Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 86

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 86
---
  
  Takeda Ireland Limited                        Kilruddery, Ireland                   Production and others                               202,679  
  Baxalta Belgium Manufacturing S. A.           Lessines, Belgium                     Production and others                               150,599  
  Takeda Manufacturing Austria AG               Vienna, Austria                       Production and others                               128,801  
  Takeda Manufacturing Italia S.p. A.           Rome, Italy                           Production and others                               111,150  
  Baxalta Manufacturing S.à r.l.                Neuchatel, Switzerland                Production and others                                87,040  
  Takeda Development Center Americas, Inc.      Cambridge, MA, U. S.                  Research, development and others                     73,382  
  Takeda Singen Real Estate GmbH & Co. KG       Singen, Germany                       Production and others                                   141  
  Takeda Pharmaceuticals U. S. A., Inc.         Cambridge, MA, U. S.                  Administrative, sales and others                          —  
  Takeda GmbH                                   Konstanz, Germany                     Production and others                                     —  
  Takeda Manufacturing Singapore Pte. Ltd.      Singapore                             Production and others                                     —  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

____________

Notes:

(1) For subsidiaries, location specified is the main location of the subsidiary. Certain production facilities may be in other locations in the country specified.

(2) Global Headquarters and Head Office consist of buildings, accompanying facilities and lands, including dormitories, company housing and other lands and facilities managed by Global Headquarters and Head Office.

Table of Contents

The following table sets forth our material new facility construction, facility removal projects and/or facilities sales projects.

  Classification      Company Name                                               Operating Segment      Details                                          Financing                Schedule                                        
                      [Main Location]                                                                                                                                                                                             
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                                 Total                  Paid                                                                                                                      
  Construction        Takeda Pharmaceutical Company Limited                      Pharmaceuticals        Manufacturing (1)                     5,582      Funds on hand            Fiscal year 2025 (2)      Fiscal year 2029 (2)  
  Construction        Baxalta US Inc.                                            Pharmaceuticals        Manufacturing (3)                    14,987      Funds on hand            January 2024              June 2027             
  Construction        Takeda Pharmaceuticals